<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04923620</url>
  </required_header>
  <id_info>
    <org_study_id>MISC-Cet-FOLFOX-SCRT</org_study_id>
    <nct_id>NCT04923620</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy</brief_title>
  <official_title>Efficacy and Safety of Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy for RAS Wild-type Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Minimally Invasive Surgery Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Minimally Invasive Surgery Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospectively Investigate the effectiveness and safety of neoadjuvant cetuximab +&#xD;
      chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS wild-type&#xD;
      locally advanced rectal cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 20, 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>two weeks after surgery</time_frame>
    <description>Tumor Regression Grade 0-1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response rate</measure>
    <time_frame>two weeks after surgery</time_frame>
    <description>Refers to the pathological examination of primary tumors and lymph node surgical specimens without residual infiltrating tumor cells (ypT0N0, TRG 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year local control rate</measure>
    <time_frame>2 years after enrollment</time_frame>
    <description>Refers to the probability of not finding local recurrence of tumor within 2 years，including anastomotic recurrence confirmed by pathological biopsy, pelvic tumor recurrence confirmed by imaging examination, or suspected pelvic recurrence with CEA exceeding the normal upper limit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year metastasis-free rate 2-year distant metastasis free rate</measure>
    <time_frame>2 years after enrollment</time_frame>
    <description>Refers to the probability of no distant metastasis within 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years after enrollment</time_frame>
    <description>Refers to the time from the start of treatment to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>2 years after enrollment</time_frame>
    <description>Refers to the time from the start of treatment to recurrence.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Neoadjuvant Treatment</condition>
  <condition>Rectal Cancer</condition>
  <condition>Cetuximab</condition>
  <condition>Radiotherapy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab+mFOLFOX6</intervention_name>
    <description>cetuximab 500mg/m2 d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>short-course radiotherapy</intervention_name>
    <description>25Gy/5Fx short-course radiotherapy between the forth and the fifth cycle of cetuximab+mFOLFOX6</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 18 to 75 years with locally advanced rectal cancer, regardless of gender,&#xD;
        ethnicity and regional distribution, were involved in this study. Patients were required to&#xD;
        be in good health and have sufficient organ function and bone marrow function.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A biopsy proven histological diagnosis of rectal adenocarcinoma；&#xD;
&#xD;
          2. An ARMS-PCR proven KRAS, NRAS, PI3KCA and BRAF wild type;&#xD;
&#xD;
          3. No intestinal obstruction, distant metastasis was excluded by CT, MRI or PET / CT;&#xD;
&#xD;
          4. MRI proven T3c-T4, CRM positive, N2, extramural vascular invasion positive or lateral&#xD;
             lymph node positive of locally advanced rectal cancer;&#xD;
&#xD;
          5. Age between 18-75 years;&#xD;
&#xD;
          6. ECOG (Eastern US Cooperative Oncology Group) score: 0-1;&#xD;
&#xD;
          7. Has sufficient organ function:&#xD;
&#xD;
               -  Hemopoietic function: hemoglobin ≥ 90 g / L, platelet ≥ 80 g / L × 109 / L,&#xD;
                  neutrophils ≥ 1.5 × 109/L&#xD;
&#xD;
               -  Liver function: ALT and AST &lt; 2.5 × ULN;&#xD;
&#xD;
               -  Renal function: serum creatinine &lt; 1.5 ULN;&#xD;
&#xD;
          8. Willing to participate and informed consent signed；&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with mutations in any of KRAS, NRAS, or BRAF, microsatellite&#xD;
             instablility-High;&#xD;
&#xD;
          2. Patients having undergone chemotherapy, radiotherapy or surgery for colorectal cancer;&#xD;
&#xD;
          3. Patients with other uncontrolled malignant tumors (except early-stage basal cell&#xD;
             carcinoma or cervical carcinoma in situ) ;&#xD;
&#xD;
          4. Female patients who are pregnant or breastfeeding;&#xD;
&#xD;
          5. Patients with severe heart, liver, or kidney, or neurological or psychiatric disease;&#xD;
&#xD;
          6. Patients with active infection;&#xD;
&#xD;
          7. Poor overall health status, ECOG ≥ 2;&#xD;
&#xD;
          8. Patients with concomitant diseases that seriously endanger the safety of patients or&#xD;
             affect the completion of the study in the judgment of the investigator;&#xD;
&#xD;
          9. Known hypersensitivity reactions to any investigational drugs;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhenghao Cai, MD</last_name>
    <phone>+862164458887</phone>
    <email>c3z2h1@alumni.sjtu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenghao Cai</last_name>
      <phone>+862164458887</phone>
      <email>c3z2h1@alumni.sjtu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 6, 2021</study_first_submitted>
  <study_first_submitted_qc>June 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Minimally Invasive Surgery Center</investigator_affiliation>
    <investigator_full_name>Cai Zhenghao</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

